Premium
Antibody‐based therapies in B‐cell lineage acute lymphoblastic leukaemia
Author(s) -
Le Jeune Caroline,
Thomas Xavier
Publication year - 2015
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12408
Subject(s) - blinatumomab , alemtuzumab , chimeric antigen receptor , cd19 , immunology , medicine , cd52 , antigen , monoclonal antibody , cd22 , antibody , cytotoxic t cell , rituximab , t cell , biology , immune system , biochemistry , in vitro
Targeted therapies represent a major breakthrough in the treatment of adult acute lymphoblastic leukaemia ( ALL ). Because lymphoblastic leukaemia cells express a variety of specific antigens, those ones can serve as targets for monoclonal antibodies (MoAbs). Anti‐ CD 20 (rituximab), anti‐ CD 19 (blinatumomab, SAR 3419), anti‐ CD 22 (epratuzumab, inotuzumab ozogamicin) and anti‐ CD 52 (alemtuzumab) have therefore been developed. Possible strategies even include recruitment of CD 3 cytotoxic T cells (blinatumomab) or adoptive T‐cell therapy by gene transfer of CD 19‐chimeric antigen receptors ( CD 19‐ CAR s). Recent data show that antibody‐based therapy is a highly promising treatment approach. However, optimal treatment approach still needs to be defined.